Atrium Therapeutics, Inc. Common Stock (RNA) - Total Assets
Based on the latest financial reports, Atrium Therapeutics, Inc. Common Stock (RNA) holds total assets worth $278.35 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check RNA total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
Atrium Therapeutics, Inc. Common Stock - Total Assets Trend (2011–2025)
This chart illustrates how Atrium Therapeutics, Inc. Common Stock's total assets have evolved over time, based on quarterly financial data. Check Atrium Therapeutics, Inc. Common Stock tangible book value ratio to evaluate the tangible quality of the company's equity base.
Atrium Therapeutics, Inc. Common Stock - Asset Composition Analysis
Current Asset Composition (December 2025)
Atrium Therapeutics, Inc. Common Stock's total assets of $278.35 Million consist of 98.0% current assets and 2.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 97.0% |
| Accounts Receivable | $12.44 Million | 4.5% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2011–2025)
This chart illustrates how Atrium Therapeutics, Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see RNA market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Atrium Therapeutics, Inc. Common Stock's current assets represent 98.0% of total assets in 2025, an increase from 0.0% in 2011.
- Cash Position: Cash and equivalents constituted 97.0% of total assets in 2025, up from 74.4% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 3.0% in 2011.
- Asset Diversification: The largest asset category is accounts receivable at 4.5% of total assets.
Atrium Therapeutics, Inc. Common Stock Competitors by Total Assets
Key competitors of Atrium Therapeutics, Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE
|
USA | $763.95 Million |
|
3SBio Inc
F:83B
|
Germany | €36.25 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497
|
China | CN¥4.48 Billion |
|
Novavax Inc
NASDAQ:NVAX
|
USA | $1.04 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Atrium Therapeutics, Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.53 | 15.73 | 17.81 |
| Quick Ratio | 6.53 | 15.73 | 17.81 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $231.04 Million | $1.44 Billion | $294.44 Million |
Atrium Therapeutics, Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between Atrium Therapeutics, Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.96 |
| Latest Market Cap to Assets Ratio | 0.71 |
| Asset Growth Rate (YoY) | -82.2% |
| Total Assets | $278.35 Million |
| Market Capitalization | $196.42 Million USD |
Valuation Analysis
Below Book Valuation: The market values Atrium Therapeutics, Inc. Common Stock's assets below their book value (0.71x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Atrium Therapeutics, Inc. Common Stock's assets decreased by 82.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Atrium Therapeutics, Inc. Common Stock (2011–2025)
The table below shows the annual total assets of Atrium Therapeutics, Inc. Common Stock from 2011 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $278.35 Million | -82.20% |
| 2024-12-31 | $1.56 Billion | +148.81% |
| 2023-12-31 | $628.55 Million | -1.60% |
| 2022-12-31 | $638.80 Million | +49.40% |
| 2021-12-31 | $427.58 Million | +28.06% |
| 2020-12-31 | $333.90 Million | +244.56% |
| 2019-12-31 | $96.91 Million | +2333.63% |
| 2018-12-31 | $3.98 Million | -96.82% |
| 2013-12-31 | $125.10 Million | +100.46% |
| 2012-12-31 | $62.41 Million | +90.97% |
| 2011-12-31 | $32.68 Million | -- |
About Atrium Therapeutics, Inc. Common Stock
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treat… Read more